Prelude Capital Management, LLC Cytosorbents Corp Transaction History

Prelude Capital Management, LLC

7 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q4 2020 Feb 16, 2021	SELL	$7.65 - $8.98 $15,300 - $17,960	-2,000 Closed	0 $0
Q3 2020 Nov 16, 2020	BUY	$7.37 - $11.54 $14,740 - $23,080	2,000 New	2,000 $16,000
Q1 2019 May 15, 2019	SELL	$6.82 - $8.56 $927 - $1,164	-136 Closed	0 $0
Q4 2018 Feb 14, 2019	SELL	$7.05 - $12.64 $9,306 - $16,684	-1,320 Reduced 90.66%	136 $1,000
Q3 2018 Nov 14, 2018	SELL	$10.95 - $14.8 $27,331 - $36,940	-2,496 Reduced 63.16%	1,456 $19,000
Q2 2018 Aug 14, 2018	BUY	$6.9 - $12.35 $12,633 - $22,612	1,831 Added 86.33%	3,952 $45,000
Q1 2018 May 15, 2018	BUY	$6.55 - $8.2 $13,892 - $17,392	2,121 New	2,121 $15,000

16.9M

10.1K

500

Ticker CTSO
Exchange NASDAQ
Sector Healthcare
Industry Medical Devices
Shares Outstandng 43,577,400
Market Cap $51.9M
Description
Cytosorbents Corporation engages in the research, development, and commercialization of medical devices with its blood purification technology platform incorporating a proprietary adsorbent and porous polymer technology. Its flagship product is CytoSorb, an extracorporeal cytokine filter for adjunctive therapy in the treatment of sepsis, adjunct...

Get notified when there are updates to the investment portfolio of Prelude Capital Management, LLC, based on Form 13F filings with the SEC.

Stay updated on Prelude Capital Management, LLC with notifications on news.